Alejandro Javier Español^1,2,*, Yamila Sanchez¹, Sofia Volpi²

BIOCELL, Vol.49, No.8, pp. 1449-1480, 2025, DOI:10.32604/biocell.2025.068034 - 29 August 2025

Abstract Background: Triple-negative (TN) breast cancer, the most aggressive subtype of breast cancer, is usually treated with high doses of paclitaxel (PX), which induces resistance. To prevent this adverse effect, metronomic chemotherapy based on administering low doses of PX plus carbachol (Carb), a muscarinic acetylcholine receptor (mAChR) agonist, has emerged as an alternative. Other acetylcholine receptors also present in breast tissue are nicotinic ones. When activated by nicotine (Nic), these receptors can decrease the effectiveness of conventional chemotherapy. However, whether metronomic chemotherapy with PX and Carb is affected by Nic has not yet been described. This… More >

Weiwei Chen¹, Xiaodie Zhou², Huiyu Li¹, Yuchen Yang¹, Lu Lu¹, Chunyan Zhu¹, Rong Fang¹, Xiaoyuan Chu¹, Shuping Zhou^3,*, Qian Sun^1,*

Oncology Research, Vol.33, No.8, pp. 2123-2139, 2025, DOI:10.32604/or.2025.063484 - 18 July 2025

Abstract Background: Primary bone marrow diffuse large B-cell lymphoma (PBM-DLBCL) represents an uncommon yet clinically aggressive hematologic malignancy. Despite its significant clinical impact, this entity lacks standardized diagnostic criteria in current WHO classifications. Methods: We performed a retrospective analysis of 55 PBM-DLBCL cases from our institutional database and published literature (2001–2022) to characterize disease features and identify prognostic factors, with particular focus on assessing how different treatment regimens influence therapeutic efficacy and long-term outcomes. Results: The data suggested a potential link between international prognostic index (IPI) scores and poorer survival, albeit without conclusive statistical evidence (p = More >

ALEX A. FRANCOEUR^*, NATALIE AYOUB, DANIELLE GREENBERG, KRISHNANSU S. TEWARI

Oncology Research, Vol.33, No.7, pp. 1511-1530, 2025, DOI:10.32604/or.2025.061120 - 26 June 2025

Abstract Endometrial cancer is the most common gynecologic cancer diagnosed in the United States and mortality is on the rise. Advanced and recurrent endometrial cancer represents a treatment challenge as historically there have been limited therapeutic options for patients. In the last several years, multiple practice-changing clinical trials have led to significant improvements in the treatment landscape. This review will cover updates in the treatment and management of advanced and recurrent endometrial cancer with a focus on novel therapeutics, such as anti-PD-L1 and PD-1 inhibitors, poly ADP-ribose polymerase (PARP) inhibitors, antibody-drug conjugates, and hormonal therapy. More >

YOUYANG HU^1,#, YISHU LUO^1,#, TIANYUE XIE¹, YUEHUA CHEN^1,2, JUN ZHAO¹, WEICHAO JI³, ZHIWEI YAN³, SITONG QIU³, KEXIN GAO³, HAIXIA ZHU⁴, LIMIN MA^1,*, QIYOU YIN^1,*

Oncology Research, Vol.33, No.7, pp. 1695-1708, 2025, DOI:10.32604/or.2025.060021 - 26 June 2025

Abstract Objective: Neuroblastoma (NB) is frequently associated with high-risk pediatric cases that demonstrate limited response to cisplatin, contributing to a poor prognosis. Recent studies have explored the role of tumor cell senescence in increasing sensitivity to this chemotherapy agent. This study aims to identify genes related to cell senescence in children diagnosed with NB, evaluate their influence on cisplatin sensitivity, and investigate potential strategies to enhance the efficacy of chemotherapy. Methods: Gene expression profiles and clinical data were obtained for 498 NB patients from the GEO database (GSE49710). The study focused on identifying genes that were… More >

NURAN BEDOLLA^#, HAO WU^#, LINYU LIU, XUETING LIU, YANLI REN^*

Oncology Research, Vol.33, No.6, pp. 1473-1484, 2025, DOI:10.32604/or.2025.060151 - 29 May 2025

Abstract Background: Gallic acid (GA), a plant-derived polyphenol, possesses diverse biological functions such as reducing inflammation and against tumors. Currently, the influence of GA on the resistance of esophageal squamous cell carcinoma (ESCC) cells to cisplatin (DDP) is not well understood. Methods: Cell counting kit-8 assay examined how GA affected KYSE30 and TE-1 cell viability. 5-Ethynyl-2′-deoxyuridine and TdT-mediated dUTP Nick-End labeling staining detected cell proliferation and apoptosis. Clone formation assay, flow cytometry, Carboxyfluorescein diacetate succinimidyl ester fluorescent probes, and Transwell assay determined cell biological properties, and 2′,7′-Dichlorofluorescin diacetate (DCFH-DA) fluorescent probes detected oxidative stress levels. Signal… More > Graphic Abstract

JIAHUI WANG^1,#, HONGCHENG GE^2,3,#, ZHENGYUAN YU^1,*, LINGZHI WU^1,*

Oncology Research, Vol.33, No.5, pp. 1033-1054, 2025, DOI:10.32604/or.2024.058256 - 18 April 2025

Abstract Lung cancer is a common cause of cancer-related death globally. The majority of lung cancer patients initially benefit from chemotherapy and immunotherapy. However, as the treatment cycle progresses and the disease evolves, the emergence of acquired resistance leads to treatment failure. Many researches have shown that non-coding RNAs (ncRNAs) not only influence lung cancer progression but also act as potential mediators of immunotherapy and chemotherapy resistance in lung cancer, mediating drug resistance by regulating multiple targets and pathways. In addition, the regulation of immune response by ncRNAs is dualistic, forming a microenvironment for inhibits/promotes More >

XI ZHU^1,2,#, KAI HUANG^3,#, XIAOMING KAO², ZHAOHUI TANG³, WENJIE GUO³, TIANCONG WU^4,*, QIURONG LI^1,2,*

Oncology Research, Vol.33, No.5, pp. 1149-1159, 2025, DOI:10.32604/or.2024.054930 - 18 April 2025

Abstract Background: Colorectal cancer (CRC) holds the third position in global cancer prevalence mortality. Although chemotherapy is a conventional treatment, recent investigations have shed light on the therapeutic potential of the cGAS cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway in CRC management. Despite the primary role of the death domain-associated protein (Daxx) in cellular apoptosis, its influence on the regulation of cGAS-STING activation remains elusive. Methods: The Daxx degradation and speck formation were conducted using immunofluorescence and Western blotting. The Daxx knock-down and over-expression in CRC cells were performed to detect in vivo and in vitro… More >

GIULIANO BERNAL^*, GISELA AQUEA, SEBASTIÁN RAMÍREZ-RIVERA

Oncology Research, Vol.33, No.4, pp. 759-779, 2025, DOI:10.32604/or.2024.057019 - 19 March 2025

Abstract Cancer remains one of the leading causes of death in the world, with more than 9 million deaths in 2022, a number that continues to rise. This highlights the urgent need for the development of new drugs, with enhanced antitumor capabilities and fewer side effects. Metal-based drugs have been used in clinical practice since the late 1970s, beginning with the introduction of cisplatin. Later, two additional platinum-based molecules, carboplatin, and oxaliplatin, were introduced, and all three continue to be widely used in the treatment of various cancers. However, despite their significant anticancer activity, the undesirable… More > Graphic Abstract

HENG ZHANG^1,#, XIAO YANG^2,#, YUJIN GUO³, HAIBO ZHAO⁴, PEI JIANG^5,*, QING-QING YU^3,*

Oncology Research, Vol.33, No.4, pp. 837-849, 2025, DOI:10.32604/or.2024.053882 - 19 March 2025

Abstract As living conditions improve and diagnostic capabilities advance, the incidence of tumors has increased, with cancer becoming a leading cause of death worldwide. Surgery, chemotherapy, and radiotherapy are the most common treatments. Despite advances in treatment options, chemotherapy remains a routine first-line treatment for most tumors. Due to the continuous and extensive use of chemotherapy drugs, tumor resistance often develops, becoming a significant cause of treatment failure and poor prognosis. Recent research has increasingly focused on how long stranded non-coding RNAs (LncRNAs) influence the development of malignant tumors and drug resistance by regulating gene expression More >

HUAFANG HUANG^1,2,#, GUILIN WANG^3,#, DONGYUN ZENG^4,5, LUZ ANGELA TORRES-DE LA ROCHE², RUI ZHUO^1,2, RUDY LEON DE WILDE², WANWAN WANG⁶, ULF D. KAHLERT^7,*, WENJIE SHI^7,*

Oncology Research, Vol.33, No.3, pp. 631-640, 2025, DOI:10.32604/or.2024.054642 - 28 February 2025

Abstract Background: Neoadjuvant chemotherapy (NAC) significantly enhances clinical outcomes in patients with triple-negative breast cancer (TNBC); however, chemoresistance frequently results in treatment failure. Consequently, understanding the mechanisms underlying resistance and accurately predicting this phenomenon are crucial for improving treatment efficacy. Methods: Ultrasound images from 62 patients, taken before and after neoadjuvant therapy, were collected. Mitochondrial-related genes were extracted from a public database. Ultrasound features associated with NAC resistance were identified and correlated with significant mitochondrial-related genes. Subsequently, a prognostic model was developed and evaluated using the GSE58812 dataset. We also assessed this model alongside clinical factors… More >